Low global warming potential (GWP) propellants are vital to the long-term sustainability of the pressurised Metered Dose Inhaler (pMDI) industry. To facilitate a successful adoption, formulations, device components and manufacturing processes will all need re-evaluating.
However, with the transition happening in advance of mandated timelines, increasing pressure is being placed on global supply chains and capabilities, risking the accessibility of life-saving medicines.
In this issue of OnDrugDelivery, Ross Errington, Head of Drug Product Development at Bespak, and Simon Gardner, Business Development Director, draw on data and expertise to explore how commercial success and a greener future can both be achieved with a proactive approach.
